| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing ipratropium (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium adverse reaction |
Causative agent (attribute) |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Allergy to ipratropium (finding) |
Causative agent (attribute) |
False |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Ipratropium bromide (substance) |
Is a |
False |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Fenoterol hydrobromide+ipratropium bromide 500micrograms/1.25mg nebulization unit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Fenoterol hydrobromide+ipratropium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Product containing ipratropium and salbutamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing fenoterol and ipratropium (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing ipratropium in nasal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing ipratropium in respiratory dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Allergy to ipratropium (finding) |
Causative agent (attribute) |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium bromide (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
|
| Ipratropium-containing product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium and salbutamol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Fenoterol and ipratropium only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium only product in nasal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing only ipratropium in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely fenoterol 500 microgram and ipratropium 1.25 milligram/1 actuation conventional release solution for inhalation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely fenoterol 500 microgram and ipratropium 1.25 milligram/1 actuation conventional release solution for inhalation (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium and salbutamol only product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Fenoterol and ipratropium only product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Product containing fenoterol and ipratropium in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium- and salbutamol-containing product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
1 |
| Ipratropium and levosalbutamol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
2 |
| Product containing ipratropium and levosalbutamol in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
2 |
| Ipratropium- and levosalbutamol-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
2 |
| Product containing only ipratropium and levosalbutamol in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ipratropium (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]